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Ionizing radiation causes a variety of DNA damages, of 
which the DNA double-strand break (DSB) stands out as 
the most hazardous type. The human body is exposed to 
different types of ionizing radiation on a daily basis. The 
most relevant source of natural radiation, comprising ap-
proximately 40 percent of a person’s annual background 
radiation, is radon gas [1]. Radon (Rn-222) is a radioac-
tive noble gas, which emits three biologically relevant α-
particles during its decay chain. Despite its radioactive 
properties, radon gas is used for its therapeutic effects in 
radon therapy caves in Bad Gastein and Bad Kreuznach 
[2].  
As part of the GREWIS project, this study is aimed at 
the biodosimetric measurement of inhaled radon gas in 
murine tissues. This project is focused on the detection of 
α-particle-induced DSB tracks in different murine tissues 
to elucidate the diffusion patterns of radon gas in vivo as 
well as potential organ-specific accumulations.  
In the past year, three independent in vivo radon exper-
iments, using a total of 18 wild type C57BL/6 mice (fe-
male, adults) were performed. A radon exposure chamber 
was used to expose the mice to a specific radon concen-
tration (40 kBq/m3 or 440 kBq/m3) for the duration of one 
hour. DSBs were visualized in paraffin-embedded tissue 
sections using highly sensitive immunofluorescence stain-
ing for 53BP1 and γH2AX [3]. Analysis of tissue sections 
of two radon-exposed mice revealed that 15 minutes after 
the end of the exposure period (440kBq/m3), excess 
53BP1 and γH2AX foci can be detected in bone (Fig.1A), 
lung (Fig.1B), heart, kidney, and liver tissues. 
As radon therapy is predominantly used for the therapy 
of chronic inflammatory diseases of the musculoskeletal 
system, a preferential accumulation of radon decay prod-
ucts in bone tissue was investigated. The current results 
do not support this hypothesis. Only a slight increase of 
DSBs, comparable to the level in heart or kidney tissue, 
was detected in bone samples. Similar levels of DSBs in 
heart, liver, bone, and kidney tissues support a model in 
which radon can diffuse freely throughout the body. 
Lung tissue sections, on the other hand, showed signifi-
cantly elevated levels of 53BP1 foci after radon exposure. 
The accumulation of DSBs in the lung is likely caused by 
the additional dose that is deposited in this organ due to 
inhaled radon progeny. As radon decays in the air, radon 
progeny, with an affinity to adhere to aerosol particles, 
are formed. These complexes subsequently enter the body 
through the respiratory tract and accumulate in the bron-
chioles where radon decay products decay further, hence 
inducing additional DNA damage. The lung is therefore 
exposed not only to inhaled radon, but also to radioactive 
radon decay products. 
Future efforts will focus on the comparison of results 
from radon-exposed mice with foci numbers from mice 
irradiated with a defined dose of X-rays in order to calcu-
late the dose deposited in specific organs after radon ex-
posure. 
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Fig.1: Visualization of DSBs: Tissue samples from mice 
exposed to 440 kBq/m3 for one hour. Animals were sacri-
ficed 15 minutes after the end of the exposure period. (A) 
Co-localizing γH2AX and 53BP1 foci in murine bone 
tissue. (B) Co-localizing γH2AX and 53BP1 foci in mu-
rine lung tissue. 
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